<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Postnatal evaluation and management of hydronephrosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Postnatal evaluation and management of hydronephrosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Postnatal evaluation and management of hydronephrosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laurence S Baskin, MD, FAAP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Duncan Wilcox, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 04, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hydronephrosis (dilation of the renal pelvis) is a common, readily diagnosed finding on antenatal ultrasound examination, which may be a transient benign condition or be associated with significant congenital anomalies of the kidney and urinary tract (CAKUT). The goal of postnatal management of infants with prenatally diagnosed hydronephrosis is to identify those with clinically significant CAKUT while avoiding unnecessary testing in patients with physiologic or clinically insignificant hydronephrosis.</p><p>Postnatal evaluation and management of infants prenatally diagnosed with hydronephrosis are reviewed here. Other related topics include:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6099.html" rel="external">"Fetal hydronephrosis: Etiology and prenatal management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6110.html" rel="external">"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)"</a> and  <a class="medical medical_review" href="/z/d/html/6106.html" rel="external">"Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6094.html" rel="external">"Clinical presentation, diagnosis, and course of primary vesicoureteral reflux"</a> and  <a class="medical medical_review" href="/z/d/html/6095.html" rel="external">"Management of vesicoureteral reflux"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6585.html" rel="external">"Congenital ureteropelvic junction obstruction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6581.html" rel="external">"Primary megaureter in infants and children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6584.html" rel="external">"Ectopic ureter"</a>.)</p><p></p><p class="headingAnchor" id="H4291764921"><span class="h1">GENERAL PRINCIPLES</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goal</strong> – The goal of the postnatal evaluation of infants with prenatally diagnosed hydronephrosis is to identify patients with congenital anomalies of the kidney and urinary tract (CAKUT) while avoiding unnecessary testing in patients with physiologic or clinically insignificant fetal hydronephrosis. The evaluation includes physical examination and imaging studies to detect abnormalities requiring postnatal intervention.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General approach</strong> – In our practice, we use an approach that entails confirming the persistence of hydronephrosis after birth and assessing the severity  (<a class="graphic graphic_algorithm graphicRef69172 graphicRef74670" href="/z/d/graphic/69172.html" rel="external">algorithm 1A-B</a>) [<a href="#rid1">1-3</a>]. The need for additional testing (eg, voiding cystourethrogram [VCUG]) is based on results of the initial postnatal ultrasound and the presence of other risk factors such as family history of clinically significant vesicoureteral reflux or CAKUT and findings of concern for neurogenic bladder (eg, imperforate anus, spinal abnormalities, myelomeningocele). This approach limits unnecessary testing and minimizes parental/caregiver's distress. (See  <a class="medical medical_review" href="/z/d/html/6099.html" rel="external">"Fetal hydronephrosis: Etiology and prenatal management", section on 'Congenital anomalies of the kidney and urinary tract (CAKUT)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urgency of evaluation</strong> – It is important to recognize that neonates with an obstructed kidney rarely require surgical intervention in the first few days or weeks after birth unless it is a solitary kidney. The fetal kidneys start to make urine between the fifth and ninth week of gestation and therefore, an additional few days and/or weeks of observation after birth awaiting an accurate diagnosis rarely affects long-term outcome. In addition, the added anesthetic risk in the neonatal period needs to be taken into account. An important exception are patients with conditions that affect both kidneys, such as posterior urethral valves (PUV). These infants generally require intervention to relieve post-bladder obstruction as soon as possible after birth to preserve kidney and bladder function. (See  <a class="medical medical_review" href="/z/d/html/6574.html" rel="external">"Management of posterior urethral valves", section on 'Postnatal management'</a>.)</p><p></p><p class="headingAnchor" id="H2250532260"><span class="h1">INITIAL POSTNATAL EVALUATION</span></p><p class="headingAnchor" id="H3952792610"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>The neonatal physical examination can identify abnormalities that are suggestive of congenital anomalies of the kidney and urinary tract (CAKUT), including the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of an abdominal mass that could represent an enlarged kidney due to obstructive uropathy or multicystic dysplastic kidney. (See  <a class="medical medical_review" href="/z/d/html/6585.html" rel="external">"Congenital ureteropelvic junction obstruction"</a> and  <a class="medical medical_review" href="/z/d/html/6144.html" rel="external">"Kidney cystic diseases in children", section on 'Multicystic dysplastic kidney'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A palpable bladder in a male infant, especially after voiding, may suggest posterior urethral valves (PUV). (See  <a class="medical medical_review" href="/z/d/html/6575.html" rel="external">"Clinical presentation and diagnosis of posterior urethral valves"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A male infant with prune-belly syndrome will have deficient abdominal wall musculature and undescended testes. (See  <a class="medical medical_review" href="/z/d/html/5002.html" rel="external">"Prune-belly syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of outer ear abnormalities is associated with an increased risk of CAKUT. (See  <a class="medical medical_review" href="/z/d/html/6299.html" rel="external">"Congenital anomalies of the ear", section on 'Association with kidney anomalies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A single umbilical artery is associated with an increased risk of CAKUT, particularly vesicoureteral reflux (VUR). (See  <a class="medical medical_review" href="/z/d/html/4984.html" rel="external">"Assessment of the newborn infant", section on 'Umbilical cord'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Spinal and/or lower extremity abnormalities suggesting a neurogenic bladder, which may result in hydronephrosis and dilated ureters. (See  <a class="medical medical_review" href="/z/d/html/6209.html" rel="external">"Myelomeningocele (spina bifida): Urinary tract complications"</a>.)</p><p></p><p class="headingAnchor" id="H2059192754"><span class="h2">Postnatal ultrasound</span><span class="headingEndMark"> — </span>The preferred initial postnatal imaging study for infants with clinically significant fetal hydronephrosis is an ultrasound examination of the kidneys and bladder. Ultrasonography can detect most CAKUT anomalies without exposing the infant to radiation [<a href="#rid4">4,5</a>].</p><p class="headingAnchor" id="H1107705919"><span class="h3">Indications</span><span class="headingEndMark"> — </span>Postnatal ultrasound evaluation is warranted if the prenatal ultrasound (performed in the third trimester) had a renal pelvic diameter (RPD) of ≥10 mm. RPDs below this level are unlikely to be associated with CAKUT. (See  <a class="medical medical_review" href="/z/d/html/6099.html" rel="external">"Fetal hydronephrosis: Etiology and prenatal management", section on 'Congenital anomalies of the kidney and urinary tract (CAKUT)'</a>.)</p><p class="headingAnchor" id="H2254704122"><span class="h3">Timing</span><span class="headingEndMark"> — </span>In general, the postnatal ultrasound examination should be avoided in the first two or three days after birth because hydronephrosis may not be detected, due to extracellular fluid shifts that will underestimate the degree of hydronephrosis. Important exceptions to this include infants with bilateral hydronephrosis associated with ureteral dilation and/or a dilated bladder and those with a hydronephrotic solitary kidney; these infants require urgent evaluation within 48 hours of birth because of they are likely to have more clinically significant CAKUT (eg, PUV) and may require early intervention  (<a class="graphic graphic_algorithm graphicRef69172" href="/z/d/graphic/69172.html" rel="external">algorithm 1A</a>). (See  <a class="medical medical_review" href="/z/d/html/6574.html" rel="external">"Management of posterior urethral valves"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bilateral hydronephrosis associated with ureteral dilation or a dilated bladder on prenatal ultrasound</strong> – Infants with bilateral hydronephrosis associated with ureteral dilation or/or a dilated bladder on prenatal ultrasound and those with concerning findings on examination (eg, a palpable bladder in a male infant) should have the postnatal ultrasound performed within 48 hours after birth  (<a class="graphic graphic_algorithm graphicRef69172" href="/z/d/graphic/69172.html" rel="external">algorithm 1A</a>). This is because these findings suggest possible post-bladder obstruction (eg, PUV) that is best managed with prompt drainage and potential surgical correction. (See  <a class="medical medical_review" href="/z/d/html/6574.html" rel="external">"Management of posterior urethral valves"</a>.)</p><p></p><p class="bulletIndent1">If the postnatal ultrasound demonstrates persistent hydronephrosis, hydroureteronephrosis, or a dilated bladder a voiding cystourethrogram (VCUG) should be performed, as discussed below. (See <a class="local">'Subsequent evaluation and management'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydronephrotic solitary kidney on prenatal ultrasound</strong> – If the prenatal ultrasound showed a hydronephrotic solitary kidney (RPD ≥10 mm on third trimester ultrasound), postnatal ultrasound is performed within 48 hours after birth. Significant hydronephrosis in a solitary kidney may be due to ureteral ectopy, ureterocele, and/or severe reflux. Prompt attention is required as these infants may require early intervention with a focus on preserving kidney function. (See  <a class="medical medical_review" href="/z/d/html/6584.html" rel="external">"Ectopic ureter"</a> and  <a class="medical medical_review" href="/z/d/html/6586.html" rel="external">"Ureterocele"</a> and  <a class="medical medical_review" href="/z/d/html/6095.html" rel="external">"Management of vesicoureteral reflux"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unilateral hydronephrosis on prenatal ultrasound</strong> – If the prenatal ultrasound showed<strong> </strong>unilateral hydronephrosis (RPD ≥10 mm on third trimester ultrasound) with an unaffected normal-appearing contralateral kidney, the postnatal ultrasound should be delayed until the infant has fully regained birth weight, indicating a normal volume status (usually two to four weeks of age). In our practice, we typically wait until two to four weeks of age  (<a class="graphic graphic_algorithm graphicRef69172" href="/z/d/graphic/69172.html" rel="external">algorithm 1A</a>). The rationale for delaying the ultrasound is that it allows the infant to return to a normal volume status as hypovolemia may decrease urinary flow and hydronephrosis may be missed or significantly reduced.</p><p></p><p class="headingAnchor" id="H3290993043"><span class="h3">Severity of hydronephrosis</span><span class="headingEndMark"> — </span>Severity of hydronephrosis is categorized according to the findings on postnatal ultrasound. Various grading systems are used in clinical practice, including classification according to the anterior-posterior RPD, the Society of Fetal Urology (SFU) grading system  (<a class="graphic graphic_diagnosticimage graphicRef50549" href="/z/d/graphic/50549.html" rel="external">image 1</a>), and the urinary tract dilation (UTD) grading system [<a href="#rid6">6-8</a>]. (See  <a class="medical medical_review" href="/z/d/html/6099.html" rel="external">"Fetal hydronephrosis: Etiology and prenatal management", section on 'Definition and grading'</a>.)</p><p>The severity according to RPD and SFU is as follows  (<a class="graphic graphic_diagnosticimage graphicRef50549" href="/z/d/graphic/50549.html" rel="external">image 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Mild hydronephrosis – RPD &lt;10 mm, SFU grades 1 and 2</p><p class="bulletIndent1"><span class="glyph">●</span>Moderate hydronephrosis – RPD 10 to 15 mm, SFU grade 3</p><p class="bulletIndent1"><span class="glyph">●</span>Severe hydronephrosis – RPD &gt;15 mm, SFU grade 4</p><p></p><p>Infants with SFU grades 3 and 4 hydronephrosis  (<a class="graphic graphic_diagnosticimage graphicRef50549" href="/z/d/graphic/50549.html" rel="external">image 1</a>) are at greatest risk for significant kidney injury and may require surgical correction [<a href="#rid4">4</a>].</p><p>The UTD grading system incorporates other parameters into the classification (eg, ureteral abnormalities, bladder abnormalities, and kidney parenchymal abnormalities) which may increase the accuracy for identifying infants who are at risk of developing kidney injury [<a href="#rid9">9-11</a>]. However, it also has higher inter-rater variability as compared with the SFU system [<a href="#rid12">12</a>]. The SFU and UTD grading systems generally are more informative than the RPD measurement alone.</p><p>Regardless of the grading system used, radiologists should include descriptors that define ureteropelvic junction (UPJ)-type hydronephrosis as opposed to a megaureter or findings consistent with posterior urethral valves.</p><p class="headingAnchor" id="H3650773287"><span class="h1">SUBSEQUENT EVALUATION AND MANAGEMENT</span><span class="headingEndMark"> — </span>Decisions regarding the need for further evaluation and antibiotic prophylaxis are based upon the severity of hydronephrosis, as assessed with postnatal ultrasonography. (See <a class="local">'Postnatal ultrasound'</a> above.)</p><p class="headingAnchor" id="H3139434473"><span class="h2">Normal ultrasound or mild hydronephrosis</span><span class="headingEndMark"> — </span>Infants with a normal postnatal ultrasound examination without any evidence of any other genitourinary abnormality (ie, no calyceal or ureteric dilation, no signs of renal dysplasia or anomalies) require no further evaluation.</p><p>For infants with mild unilateral hydronephrosis on postnatal ultrasound (renal pelvic diameter [RPD] 5 to &lt;10 mm), the need for follow-up imaging depends on when the postnatal ultrasound was performed:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early postnatal ultrasound</strong> – If the postnatal ultrasound was performed in the early neonatal period (within the first three weeks after birth), we suggest repeating the ultrasound at four to six months of age. This is because clinically significant hydronephrosis may not be seen on early postnatal imaging, due to relative dehydration in the early newborn period.</p><p></p><p class="bulletIndent1">Prophylactic antibiotic therapy is <strong>not</strong> necessary while awaiting the follow-up ultrasound, as discussed below. (See <a class="local">'Antibiotic prophylaxis'</a> below.)</p><p></p><p class="bulletIndent1">However, if the infant develops a urinary tract infection (UTI) during the observation period, they should be treated with antibiotics and should undergo further evaluation with voiding cystourethrogram (VCUG).</p><p></p><p class="bulletIndent1">If the infant has no UTIs and the ultrasound findings at four to six months are improved or stable, this confirms the diagnosis of transitional hydronephrosis and further urologic follow-up is not necessary.</p><p></p><p class="bulletIndent1">If the follow-up ultrasound shows worsening hydronephrosis (RPD ≥10 mm), the infant should undergo additional evaluation, as discussed below.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Later postnatal ultrasound</strong> – If the initial postnatal ultrasound was performed after three to four weeks of age and showed only mild hydronephrosis, no further evaluation is necessary.</p><p></p><p>This approach is supported by follow-up data at two years of age and at 12 and 15 years of age that reported excellent outcomes for infants with resolved or mild hydronephrosis on postnatal ultrasound [<a href="#rid13">13,14</a>].</p><p class="headingAnchor" id="H3324068088"><span class="h2">Persistent moderate to severe hydronephrosis</span><span class="headingEndMark"> — </span>Infants with a persistent moderate to severe hydronephrosis (RPD ≥10 mm) on postnatal ultrasound generally require additional evaluation. The choice of imaging test depends on whether the ultrasound findings are concerning for possible posterior urethral valves (PUV) or vesicoureteral reflux (VUR) or whether they suggest ureteropelvic junction (UPJ) obstruction.</p><p class="headingAnchor" id="H1470163902"><span class="h3">Findings concerning for PUV or VUR</span><span class="headingEndMark"> — </span>For infants with either of the following findings on postnatal ultrasound, the next step in the evaluation is a VCUG  (<a class="graphic graphic_algorithm graphicRef74670" href="/z/d/graphic/74670.html" rel="external">algorithm 1B</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Bilateral hydronephrosis of any severity</p><p class="bulletIndent1"><span class="glyph">●</span>Hydronephrosis associated with ureteral or bladder dilation</p><p></p><p>The VCUG is done to identify patients with bladder outlet obstruction (most commonly PUV) and to detect VUR. The latter accounts for approximately 10 percent of cases of neonatal hydronephrosis [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/6094.html" rel="external">"Clinical presentation, diagnosis, and course of primary vesicoureteral reflux"</a>.)</p><p>The VCUG is performed under fluoroscopy. A urinary catheter is inserted into the bladder, contrast material is instilled, and images are obtained while the bladder fills and during voiding. Infants usually tolerate this procedure well. Although the duration of fluoroscopy is minimized, the gonads, especially the ovaries, are exposed to radiation [<a href="#rid16">16</a>]. Newer techniques with radiopaque contrast bubbles detected by sonography thereby avoiding radiation are used in some centers [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/6094.html" rel="external">"Clinical presentation, diagnosis, and course of primary vesicoureteral reflux", section on 'Imaging'</a>.)</p><p class="headingAnchor" id="H2227404067"><span class="h3">Findings suggestive of ureteropelvic junction obstruction</span><span class="headingEndMark"> — </span>For patients in whom the postnatal ultrasound suggests classic UPJ-type obstruction (ie, unilateral moderate to severe hydronephrosis with nondilated ureter, normal bladder, and normal contralateral kidney), the diagnosis is confirmed with diuretic renal scan, typically performed after six weeks of age. Magnetic resonance imaging can also be used to make the diagnosis. (See <a class="local">'Specialized imaging studies'</a> below and  <a class="medical medical_review" href="/z/d/html/6585.html" rel="external">"Congenital ureteropelvic junction obstruction", section on 'Diagnosis'</a>.)</p><p>Congenital UPJ obstruction is the most common pathologic cause of prenatally diagnosed hydronephrosis. In our practice, we do not routinely perform VCUGs in these patients. Other experts routinely perform VCUG to definitively exclude VUR since a small minority of patients with UPJ obstruction may also have VUR. Historically, VCUG was performed in all patients with findings suggestive of UPJ obstruction; however, accumulating evidence suggests that infants with classic UPJ-type obstruction have a low risk of significant VUR. Therefore, we feel VCUG is not warranted in this group of patients [<a href="#rid18">18,19</a>].</p><p>The diagnosis of UPJ obstruction is discussed in greater detail separately.(See  <a class="medical medical_review" href="/z/d/html/6585.html" rel="external">"Congenital ureteropelvic junction obstruction", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H3916962237"><span class="h3">Follow-up after voiding cystourethrogram</span><span class="headingEndMark"> — </span>For infants who undergo VCUG, the need for further evaluation is determined as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>If bladder outlet obstruction (eg, PUV) is detected</strong> – The hallmark finding on VCUG that suggests PUV is a dilated and elongated posterior urethra during the voiding phase (in the absence of a urethral catheter)  (<a class="graphic graphic_diagnosticimage graphicRef62496" href="/z/d/graphic/62496.html" rel="external">image 2</a>). The next step is to perform cystoscopy to confirm the diagnosis and ablate the PUV. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6575.html" rel="external">"Clinical presentation and diagnosis of posterior urethral valves", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/6574.html" rel="external">"Management of posterior urethral valves", section on 'Cystoscopy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>If reflux is detected</strong> – If the VCUG detects VUR, therapeutic options are discussed with the family/caregivers and include observation, medical management including antibiotic prophylaxis, or surgical correction for more severe grades of reflux. Management of VUR is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6095.html" rel="external">"Management of vesicoureteral reflux", section on 'Therapeutic options'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>If there is no reflux on VCUG</strong> – If the VCUG does <strong>not</strong> show VUR, further evaluation depends upon the degree of hydronephrosis  (<a class="graphic graphic_algorithm graphicRef74670" href="/z/d/graphic/74670.html" rel="external">algorithm 1B</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe hydronephrosis</strong> – In our center, infants with persistent postnatal <strong>severe</strong> hydronephrosis (RPD &gt;15 mm) undergo further testing with a diuretic renography to detect possible obstruction. (See <a class="local">'Diuretic renography'</a> below.)</p><p></p><p class="bulletIndent2">At this stage of evaluation, referral to a center with expertise in pediatric urologic care is warranted because the renal scan is an invasive procedure requiring placement of an intravenous line and bladder catheter, and surgical interventions may be required if the kidney is obstructed. In general, diuretic renography can be performed after six weeks of life because surgical intervention is rarely required prior to this time (eg, severe hydronephrosis without VUR).</p><p></p><p class="bulletIndent2">The role of antibiotic prophylaxis in patients with severe hydronephrosis without VUR is discussed below. (See <a class="local">'Antibiotic prophylaxis'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate hydronephrosis</strong> – In our center, infants with <strong>moderate</strong> postnatal hydronephrosis (RPD 10 to 15 mm) have a repeat ultrasound when they reach four to six months of age. Further management decisions are made based on the subsequent ultrasound  (<a class="graphic graphic_algorithm graphicRef74670" href="/z/d/graphic/74670.html" rel="external">algorithm 1B</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Resolution</strong> – Most cases of mild to moderate postnatal hydronephrosis resolve by 18 months of age [<a href="#rid20">20-22</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>No change</strong> – If there is no change on the follow-up ultrasound, we continue to monitor the degree of hydronephrosis with an ultrasound performed at one year of age, and if needed, between three and five years of age. If the patient develops symptoms (eg, abdominal pain, hematuria), or if the RPD increases, diuretic renography may be performed to determine if there is an obstructive process. (See <a class="local">'Diuretic renography'</a> below.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Worsening hydronephrosis</strong> – If the degree of hydronephrosis increases, diuretic renography is performed to determine if there is an obstructive process. (See <a class="local">'Diuretic renography'</a> below.)</p><p></p><p class="bulletIndent3">This scenario is uncommon. In a retrospective study of 344 patients with prenatally diagnosed hydronephrosis that persisted on prenatal ultrasound and whose evaluation did not reveal a condition requiring intervention, only four patients (1 percent) subsequently developed worsening hydronephrosis [<a href="#rid23">23</a>]. All four patients presented with clinical symptoms of intermittent UPJ obstruction (eg, abdominal pain, gross hematuria, and vomiting).</p><p></p><p class="headingAnchor" id="H2682081114"><span class="h2">Prevention of urinary tract infection</span><span class="headingEndMark"> — </span>Higher rates of urinary tract infections (UTIs) have been reported in infants with prenatally diagnosed hydronephrosis compared with the general pediatric population [<a href="#rid24">24-28</a>]. The risk of infection rises if there is underlying VUR and is greater in girls compared with boys [<a href="#rid26">26,28,29</a>]. The risk also rises with the severity of hydronephrosis [<a href="#rid30">30</a>].</p><p>In our practice, interventions used to reduce the risk of UTI include judicious use of antibiotic prophylaxis and treatment of physiologic phimosis with local steroid ointment in male infants with hydronephrosis.</p><p class="headingAnchor" id="H14"><span class="h3">Antibiotic prophylaxis</span><span class="headingEndMark"> — </span>The role of prophylactic antibiotics in infants undergoing diagnostic evaluation for prenatally diagnosed hydronephrosis remains uncertain. It had been postulated that hydronephrosis was a risk factor for UTI due to urinary stasis; however, accumulating data suggest that antibiotic prophylaxis may not be beneficial for patients with low-grade VUR and those with UPJ obstruction, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6095.html" rel="external">"Management of vesicoureteral reflux", section on 'Antibiotic prophylaxis'</a> and  <a class="medical medical_review" href="/z/d/html/6585.html" rel="external">"Congenital ureteropelvic junction obstruction", section on 'Antibiotic prophylaxis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – In our practice, we do <strong>not</strong> administer antibiotic prophylaxis to infants undergoing evaluation for prenatally diagnosed hydronephrosis if the hydronephrosis is low- to moderate-grade (ie, RPD ≤12 mm, SFU [Society of Fetal Urology] grades 1, 2, or 3  (<a class="graphic graphic_diagnosticimage graphicRef50549" href="/z/d/graphic/50549.html" rel="external">image 1</a>)) or if the findings suggest classic unilateral UPJ obstruction (ie, unilateral hydronephrosis with nondilated ureter, normal bladder, and normal contralateral kidney) [<a href="#rid13">13,31</a>]. Other centers provide prophylactic antibiotics for moderate hydronephrosis (ie, RPD between 10 to 15 mm).</p><p></p><p class="bulletIndent1">We reserve antibiotic prophylaxis for patients with any of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dilated ureters (ectopic or refluxing)</p><p class="bulletIndent2"><span class="glyph">•</span>An enlarged bladder (suggestive of PUV)</p><p class="bulletIndent2"><span class="glyph">•</span>Bilateral UPJ obstruction</p><p class="bulletIndent2"><span class="glyph">•</span>Giant hydronephrosis (massively enlarged kidney with RPD &gt;30 mm)</p><p></p><p class="bulletIndent1">This approach is supported by observational studies. In a systematic review and meta-analysis that included 21 observational studies, the following findings were noted [<a href="#rid31">31</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with low-grade hydronephrosis (SFU grades 1 and 2; n = 2181), rates of UTI were similar between patients treated with or without antibiotic prophylaxis (2.2 versus 2.8 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In contrast, patients with high-grade hydronephrosis (SFU grades 3 and 4; n = 507) who received antibiotic prophylaxis had a lower rate of UTI compared with those who were not treated with antibiotics (15 versus 29 percent).</p><p></p><p class="bulletIndent1">In our practice, patients with SFU grade 3 hydronephrosis are typically not given antibiotic prophylaxis unless there is a family history of UTI, VUR, or other uropathy [<a href="#rid32">32</a>]. However, practice varies and other centers routinely provide prophylactic antibiotics for patients with SFU grade 3 hydronephrosis.</p><p></p><p class="bulletIndent1">The role of antibiotic prophylaxis in infants with confirmed VUR or UPJ obstruction is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6095.html" rel="external">"Management of vesicoureteral reflux", section on 'Antibiotic prophylaxis'</a> and  <a class="medical medical_review" href="/z/d/html/6585.html" rel="external">"Congenital ureteropelvic junction obstruction", section on 'Antibiotic prophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic regimen</strong> – When prophylactic antibiotic therapy is warranted, the choice of antibiotic depends on postnatal age:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age &lt;2 months – For this age group, we use <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a> unless the infant has a penicillin allergy. The dose for amoxicillin prophylaxis is 10 to 15 mg/kg orally once daily. <a class="drug drug_pediatric" data-topicid="13138" href="/z/d/drug information/13138.html" rel="external">Cephalexin</a> (10 mg/kg orally once daily) is a reasonable alternative. We use these antibiotics because alternative antibiotics (<a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a> or <a class="drug drug_pediatric" data-topicid="12645" href="/z/d/drug information/12645.html" rel="external">nitrofurantoin</a>) are associated with serious adverse effects (eg, hyperbilirubinemia) in this age group and should be avoided.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age ≥2 months – After two months of age, we switch to either <a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">trimethoprim-sulfamethoxazole</a> (2 to 3 mg/kg <a class="drug drug_pediatric" data-topicid="12865" href="/z/d/drug information/12865.html" rel="external">trimethoprim</a> component orally once daily, maximum 80 mg/dose) or <a class="drug drug_pediatric" data-topicid="12645" href="/z/d/drug information/12645.html" rel="external">nitrofurantoin</a> (1 to 2 mg/kg orally once daily, maximum 100 mg/dose). These antibiotics are preferred over <a class="drug drug_pediatric" data-topicid="12631" href="/z/d/drug information/12631.html" rel="external">amoxicillin</a>, <a class="drug drug_pediatric" data-topicid="12683" href="/z/d/drug information/12683.html" rel="external">ampicillin</a>, or cephalosporins because they have lower rates of antibiotic resistance.</p><p></p><p class="headingAnchor" id="H1630587047"><span class="h3">Uncircumcised males</span><span class="headingEndMark"> — </span>The risk of UTI is higher in males who are not circumcised. In our practice, we review the care of the uncircumcised penis with parents/caregivers and, if appropriate, treatment of physiologic phimosis with topical steroid ointment. (See  <a class="medical medical_review" href="/z/d/html/14539.html" rel="external">"Care and complications of the uncircumcised penis in infants and children", section on 'Management of pathologic phimosis'</a>.)</p><p>We no longer routinely recommend circumcision to parents/caregivers of uncircumcised neonatal males with hydronephrosis. We review the data with the parents/caregivers regarding the risk of recurrent UTI in uncircumcised males with hydronephrosis [<a href="#rid27">27</a>] and offer the option of circumcision as a potential intervention to decrease the risk for future UTI. (See  <a class="medical medical_review" href="/z/d/html/6716.html" rel="external">"Neonatal circumcision: Risks and benefits", section on 'Reduction in urinary tract infection'</a>.)</p><p class="headingAnchor" id="H92596102"><span class="h1">SPECIALIZED IMAGING STUDIES</span></p><p class="headingAnchor" id="H2582241804"><span class="h2">Diuretic renography</span><span class="headingEndMark"> — </span>Diuretic renography (renal scan and the administration of a diuretic, typically <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">furosemide</a>) is used to diagnose urinary tract obstruction in infants with severe persistent hydronephrosis after a voiding cystourethrogram (VCUG) has demonstrated no vesicoureteral reflux (VUR) [<a href="#rid33">33</a>]. It measures the drainage time from the renal pelvis and assesses the relative contribution of each kidney to overall kidney function.</p><p>The test requires insertion of a bladder catheter to relieve any pressure that can be transmitted to the ureters and kidneys. Intravenous access is needed for hydration and the administration of the radioisotope and diuretic. The preferred radioisotope is technetium-99m-mercaptoacetyltriglycine (Tc99mMAG3), which is taken up by the renal cortex, filtered across the glomerular basement membrane (GBM) to the renal tubules, and excreted into the renal pelvis and urinary tract [<a href="#rid34">34</a>].</p><p>The study includes two phases:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial phase</strong> – Radioisotope is injected intravenously, and kidney parenchymal (cortical) uptake is measured during the first two to three minutes. The relative contribution of each kidney to overall kidney function, referred to as "split kidney function," is assessed quantitatively. Split kidney function is the most useful measure to detect differences in kidney function between the two kidneys. As a rule of thumb, spilt kidney function of less than 5 percent difference is unlikely to be clinically significant.</p><p></p><p class="bulletIndent1">In patients with unilateral hydronephrosis (which is the most common clinical scenario), if the normal nonhydronephrotic kidney and hydronephrotic kidney both have similar function (ie, difference in split kidney function &lt;5 percent), conservative management without surgery is a safe option. Subsequent studies can be compared with the initial baseline scan to determine whether kidney function remains stable or whether increasing differences in split kidney function develop that indicate a decrease in the function of the hydronephrotic kidney, most likely due to significant obstruction, which may require intervention [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second phase</strong> – In the second phase, at peak kidney uptake, intravenous <a class="drug drug_pediatric" data-topicid="13329" href="/z/d/drug information/13329.html" rel="external">furosemide</a> is administered and the excretion of isotope from the kidney is measured (referred to as the "washout curve"). This phase indicates the extent of obstruction, if present. In the normal kidney, the administration of furosemide results in a prompt washout. In a dilated system, if washout occurs rapidly after diuretic administration (&lt;15 minutes), the system is not obstructed. If washout is delayed beyond 20 minutes, the pattern is consistent with obstructive uropathy. However, a delayed washout must be interpreted with caution [<a href="#rid36">36,37</a>]. As an example, in a series of 39 infants with antenatal unilateral hydronephrosis followed without surgery, diuretic renography indicated obstruction in 24 patients whose kidney function never decreased and thus could not have been obstructed [<a href="#rid37">37</a>]. These results may partly be due to the normally low neonatal glomerular filtration rate that can be refractory to diuretic therapy. If washout is between 15 and 20 minutes, the study is considered indeterminate.</p><p></p><p>A number of factors can affect the accuracy of the diuretic renogram. This includes the state of hydration of the infant, the functionality of the bladder catheter, the timing of diuretic administration, the accuracy of physically outlining the kidney tissue in the presence of severe hydronephrosis, and the background effect from the liver and spleen.</p><p class="headingAnchor" id="H3025276039"><span class="h2">Magnetic resonance urography</span><span class="headingEndMark"> — </span>Magnetic resonance urography (MRU) in children is becoming more commonly used in the diagnosis and management of congenital uropathies, such as ureteropelvic junction (UPJ) obstruction [<a href="#rid38">38,39</a>]. MRU is especially useful in the management of obstructed kidneys that have rotation or ascent anomalies, or are single. MRU can more clearly define the anatomy and delineate the proper surgical approach (ie, retroperitoneal versus transperitoneal). The disadvantage of MRU is that the study often requires general anesthesia or heavy conscious sedation in infants and children. However, for patients in the newborn period, many centers are now performing "swaddle MRI" after the infant falls asleep after feeding, thus avoiding general anesthesia and conscious sedation. Another disadvantage is the use of the contrast agent gadolinium, which can only be used if the kidney function is normal (requiring a preprocedure serum creatinine test) because of reports of irreversible renal fibrosis in patients with kidney insufficiency. Newer MRU technology may even define obstruction, eliminating the need for diuretic renal scans.</p><p class="headingAnchor" id="H2737307"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/16335.html" rel="external">"Patient education: Hydronephrosis in babies (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> – Hydronephrosis (dilation of the renal pelvis) is a common finding on antenatal ultrasound examination. It may be a transient benign condition, or it may indicate a significant congenital anomaly of the kidney and urinary tract (CAKUT). The goal of the postnatal evaluation is to identify patients with clinically significant CAKUT while avoiding unnecessary testing in patients with physiologic or clinically insignificant fetal hydronephrosis. (See <a class="local">'General principles'</a> above and  <a class="medical medical_review" href="/z/d/html/6099.html" rel="external">"Fetal hydronephrosis: Etiology and prenatal management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications for postnatal ultrasound</strong> – Postnatal ultrasound evaluation is warranted if the prenatal ultrasound (performed in the third trimester) had a renal pelvic diameter (RPD) of ≥10 mm. (See <a class="local">'Indications'</a> above and  <a class="medical medical_review" href="/z/d/html/6099.html" rel="external">"Fetal hydronephrosis: Etiology and prenatal management", section on 'Congenital anomalies of the kidney and urinary tract (CAKUT)'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Timing of postnatal ultrasound</strong> – For most infants, the postnatal ultrasound should be deferred until two to four weeks after birth to allow time for early neonatal fluid shifts to resolve  (<a class="graphic graphic_algorithm graphicRef69172" href="/z/d/graphic/69172.html" rel="external">algorithm 1A</a>). Important exceptions to this include infants with bilateral hydronephrosis associated with ureteral dilation or a dilated bladder and those with a hydronephrotic solitary kidney. Infants with these findings require urgent evaluation within 48 hours of birth because of they are likely to have more clinically significant CAKUT (eg, posterior urethral valves [PUV]) and may require early intervention. (See <a class="local">'Timing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severity of hydronephrosis</strong> – The severity of hydronephrosis is categorized according to the findings on postnatal ultrasound  (<a class="graphic graphic_diagnosticimage graphicRef50549" href="/z/d/graphic/50549.html" rel="external">image 1</a>) (see <a class="local">'Severity of hydronephrosis'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Mild hydronephrosis (grades 1 and 2) – RPD &lt;10 mm</p><p class="bulletIndent3"><span class="glyph">-</span>Moderate hydronephrosis (grade 3) – RPD 10 to 15 mm</p><p class="bulletIndent3"><span class="glyph">-</span>Severe hydronephrosis (grade 4) – RPD &gt;15 mm</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent evaluation</strong> – The need for additional testing depends on the severity of hydronephrosis on postnatal ultrasound  (<a class="graphic graphic_algorithm graphicRef74670" href="/z/d/graphic/74670.html" rel="external">algorithm 1B</a>). (See <a class="local">'Subsequent evaluation and management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Normal postnatal ultrasound</strong> – No further evaluation is required. (See <a class="local">'Normal ultrasound or mild hydronephrosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild hydronephrosis (RPD 5 to &lt;10 mm)</strong> – The need for repeat imaging depends on the timing of the postnatal ultrasound. If it was performed in the early neonatal period (within the first three weeks after birth), we suggest repeating the ultrasound at four to six months of age. If the postnatal ultrasound was performed after three to four weeks of age and showed only mild hydronephrosis, no additional evaluation is necessary. (See <a class="local">'Normal ultrasound or mild hydronephrosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate to severe hydronephrosis</strong> – Infants with persistent moderate to severe hydronephrosis (RPD ≥10 mm) on postnatal ultrasound generally require additional evaluation. The choice of imaging test is as follows  (<a class="graphic graphic_algorithm graphicRef74670" href="/z/d/graphic/74670.html" rel="external">algorithm 1B</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the postnatal ultrasound shows ureteral or bladder dilation or if there is bilateral hydronephrosis, a voiding cystourethrogram (VCUG) is performed to detect the presence of vesicoureteral reflux (VUR) or PUVs. (See <a class="local">'Persistent moderate to severe hydronephrosis'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients in whom the postnatal ultrasound suggests classic ureteropelvic junction (UPJ)-type obstruction (ie, unilateral moderate to severe hydronephrosis with nondilated ureter, normal bladder, and normal contralateral kidney), the diagnosis is confirmed with diuretic renal scan and VCUG is generally not necessary. (See  <a class="medical medical_review" href="/z/d/html/6585.html" rel="external">"Congenital ureteropelvic junction obstruction", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Follow-up after VCUG</strong> – Evaluation and management based on the VCUG findings is as follows:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>If VUR or PUV are detected</strong> – Management options for VUR include observation, medical management (including antibiotic prophylaxis), and/or surgical correction for severe VUR. PUVs are managed surgically. These conditions are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6095.html" rel="external">"Management of vesicoureteral reflux"</a> and  <a class="medical medical_review" href="/z/d/html/6574.html" rel="external">"Management of posterior urethral valves"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>No reflux and severe hydronephrosis</strong> – Diuretic renography is performed to detect possible obstruction for infants with severe hydronephrosis (RPD &gt;15 mm) and no VUR. At this stage of evaluation, referral to a center with expertise in pediatric urologic care is warranted. (See <a class="local">'Diuretic renography'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>No reflux and moderate hydronephrosis</strong> – Ultrasound examination is repeated at four to six months of age. In most cases, hydronephrosis will have resolved by this age. For infants with increased hydronephrosis at six months, a diuretic renal scan is performed. (See <a class="local">'Diuretic renography'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of urinary tract infections</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prophylactic antibiotics</strong> – The role of antibiotic prophylaxis in infants undergoing diagnostic evaluation for prenatally diagnosed hydronephroses is uncertain. We suggest antibiotic prophylaxis for patients with any of the following (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>)  (<a class="graphic graphic_algorithm graphicRef69172" href="/z/d/graphic/69172.html" rel="external">algorithm 1A</a>) (see <a class="local">'Antibiotic prophylaxis'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Dilated ureters</p><p class="bulletIndent3"><span class="glyph">-</span>Enlarged bladder</p><p class="bulletIndent3"><span class="glyph">-</span>Bilateral UPJ obstruction</p><p class="bulletIndent3"><span class="glyph">-</span>Giant hydronephrosis (massively enlarged kidney with RPD &gt;30 mm)</p><p></p><p class="bulletIndent2">We do not routinely prescribe prophylactic antibiotics for infants with milder degrees of hydronephrosis (ie, RPD ≤12 mm; grades 1, 2, 3  (<a class="graphic graphic_diagnosticimage graphicRef50549" href="/z/d/graphic/50549.html" rel="external">image 1</a>)) and those with classic unilateral UPJ obstruction. Other centers provide prophylactic antibiotics for moderate hydronephrosis (ie, RPD between 10 to 15 mm).</p><p></p><p class="bulletIndent2">The role of antibiotic prophylaxis in infants with confirmed VUR or UPJ obstruction is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6095.html" rel="external">"Management of vesicoureteral reflux", section on 'Antibiotic prophylaxis'</a> and  <a class="medical medical_review" href="/z/d/html/6585.html" rel="external">"Congenital ureteropelvic junction obstruction", section on 'Antibiotic prophylaxis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Uncircumcised males</strong> – Measures to reduce the risk of urinary tract infection (UTI) in uncircumcised males are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/14539.html" rel="external">"Care and complications of the uncircumcised penis in infants and children", section on 'Management of pathologic phimosis'</a> and  <a class="medical medical_review" href="/z/d/html/6716.html" rel="external">"Neonatal circumcision: Risks and benefits", section on 'Infants with congenital uropathy'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Josephson S. Antenatally detected pelvi-ureteric junction obstruction: concerns about conservative management. BJU Int 2000; 85:973.</a></li><li><a class="nounderline abstract_t">Ransley PG, Dhillon HK, Gordon I, et al. The postnatal management of hydronephrosis diagnosed by prenatal ultrasound. J Urol 1990; 144:584.</a></li><li><a class="nounderline abstract_t">Josephson S, Dhillon HK, Ransley PG. Post-natal management of antenatally detected, bilateral hydronephrosis. Urol Int 1993; 51:79.</a></li><li><a class="nounderline abstract_t">Dias CS, Silva JM, Pereira AK, et al. Diagnostic accuracy of renal pelvic dilatation for detecting surgically managed ureteropelvic junction obstruction. J Urol 2013; 190:661.</a></li><li><a class="nounderline abstract_t">Coplen DE, Austin PF, Yan Y, et al. The magnitude of fetal renal pelvic dilatation can identify obstructive postnatal hydronephrosis, and direct postnatal evaluation and management. J Urol 2006; 176:724.</a></li><li><a class="nounderline abstract_t">Onen A. Grading of Hydronephrosis: An Ongoing Challenge. Front Pediatr 2020; 8:458.</a></li><li><a class="nounderline abstract_t">Nguyen HT, Benson CB, Bromley B, et al. Multidisciplinary consensus on the classification of prenatal and postnatal urinary tract dilation (UTD classification system). J Pediatr Urol 2014; 10:982.</a></li><li><a class="nounderline abstract_t">Cakici EK, Aydog O, Eroglu FK, et al. Value of renal pelvic diameter and urinary tract dilation classification in the prediction of urinary tract anomaly. Pediatr Int 2019; 61:271.</a></li><li><a class="nounderline abstract_t">Melo FF, Vasconcelos MA, Mak RH, et al. Postnatal urinary tract dilatation classification: improvement of the accuracy in predicting kidney injury. Pediatr Nephrol 2022; 37:613.</a></li><li><a class="nounderline abstract_t">Melo FF, Mak RH, Simões E Silva AC, et al. Evaluation of Urinary Tract Dilation Classification System for Prediction of Long-Term Outcomes in Isolated Antenatal Hydronephrosis: A Cohort Study. J Urol 2021; 206:1022.</a></li><li><a class="nounderline abstract_t">Zhang H, Zhang L, Guo N. Validation of "urinary tract dilation" classification system: Correlation between fetal hydronephrosis and postnatal urological abnormalities. Medicine (Baltimore) 2020; 99:e18707.</a></li><li><a class="nounderline abstract_t">Rickard M, Easterbrook B, Kim S, et al. Six of one, half a dozen of the other: A measure of multidisciplinary inter/intra-rater reliability of the society for fetal urology and urinary tract dilation grading systems for hydronephrosis. J Pediatr Urol 2017; 13:80.e1.</a></li><li><a class="nounderline abstract_t">Lidefelt KJ, Herthelius M, Soeria-Atmadja S. Antenatal renal pelvis dilatation: 2-year follow-up with DMSA scintigraphy. Pediatr Nephrol 2009; 24:533.</a></li><li><a class="nounderline abstract_t">Herthelius M, Axelsson R, Lidefelt KJ. Antenatally detected urinary tract dilatation: a 12-15-year follow-up. Pediatr Nephrol 2020; 35:2129.</a></li><li><a class="nounderline abstract_t">Lidefelt KJ, Ek S, Mihocsa L. Is screening for vesicoureteral reflux mandatory in infants with antenatal renal pelvis dilatation? Acta Paediatr 2006; 95:1653.</a></li><li><a class="nounderline abstract_t">Woodward M, Frank D. Postnatal management of antenatal hydronephrosis. BJU Int 2002; 89:149.</a></li><li><a class="nounderline abstract_t">Barnewolt CE, Acharya PT, Aguirre Pascual E, et al. Contrast-enhanced voiding urosonography part 2: urethral imaging. Pediatr Radiol 2021; 51:2368.</a></li><li><a class="nounderline abstract_t">Hubertus J, Plieninger S, Martinovic V, et al. Children and adolescents with ureteropelvic junction obstruction: is an additional voiding cystourethrogram necessary? Results of a multicenter study. World J Urol 2013; 31:683.</a></li><li><a class="nounderline abstract_t">Weitz M, Schmidt M. To screen or not to screen for vesicoureteral reflux in children with ureteropelvic junction obstruction: a systematic review. Eur J Pediatr 2017; 176:1.</a></li><li><a class="nounderline abstract_t">Mamì C, Paolata A, Palmara A, et al. Outcome and management of isolated moderate renal pelvis dilatation detected at postnatal screening. Pediatr Nephrol 2009; 24:2005.</a></li><li><a class="nounderline abstract_t">Alconcher LF, Tombesi MM. Natural history of bilateral mild isolated antenatal hydronephrosis conservatively managed. Pediatr Nephrol 2012; 27:1119.</a></li><li><a class="nounderline abstract_t">Sidhu G, Beyene J, Rosenblum ND. Outcome of isolated antenatal hydronephrosis: a systematic review and meta-analysis. Pediatr Nephrol 2006; 21:218.</a></li><li><a class="nounderline abstract_t">Matsui F, Shimada K, Matsumoto F, Takano S. Late recurrence of symptomatic hydronephrosis in patients with prenatally detected hydronephrosis and spontaneous improvement. J Urol 2008; 180:322.</a></li><li><a class="nounderline abstract_t">Dacher JN, Mandell J, Lebowitz RL. Urinary tract infection in infants in spite of prenatal diagnosis of hydronephrosis. Pediatr Radiol 1992; 22:401.</a></li><li><a class="nounderline abstract_t">Walsh TJ, Hsieh S, Grady R, Mueller BA. Antenatal hydronephrosis and the risk of pyelonephritis hospitalization during the first year of life. Urology 2007; 69:970.</a></li><li><a class="nounderline abstract_t">Visuri S, Jahnukainen T, Taskinen S. Incidence of urinary tract infections in infants with antenatally diagnosed hydronephrosis-A retrospective single center study. J Pediatr Surg 2017; 52:1503.</a></li><li><a class="nounderline abstract_t">Ellison JS, Dy GW, Fu BC, et al. Neonatal Circumcision and Urinary Tract Infections in Infants With Hydronephrosis. Pediatrics 2018; 142.</a></li><li><a class="nounderline abstract_t">Pennesi M, Amoroso S, Bassanese G, et al. Frequency of urinary tract infection in children with antenatal diagnosis of urinary tract dilatation. Arch Dis Child 2020; 105:260.</a></li><li><a class="nounderline abstract_t">Coelho GM, Bouzada MC, Lemos GS, et al. Risk factors for urinary tract infection in children with prenatal renal pelvic dilatation. J Urol 2008; 179:284.</a></li><li><a class="nounderline abstract_t">Szymanski KM, Al-Said AN, Pippi Salle JL, Capolicchio JP. Do infants with mild prenatal hydronephrosis benefit from screening for vesicoureteral reflux? J Urol 2012; 188:576.</a></li><li><a class="nounderline abstract_t">Braga LH, Mijovic H, Farrokhyar F, et al. Antibiotic prophylaxis for urinary tract infections in antenatal hydronephrosis. Pediatrics 2013; 131:e251.</a></li><li><a class="nounderline abstract_t">Lidefelt KJ, Herthelius M. Antenatal hydronephrosis: infants with minor postnatal dilatation do not need prophylaxis. Pediatr Nephrol 2008; 23:2021.</a></li><li><a class="nounderline abstract_t">Chung S, Majd M, Rushton HG, Belman AB. Diuretic renography in the evaluation of neonatal hydronephrosis: is it reliable? J Urol 1993; 150:765.</a></li><li><a class="nounderline abstract_t">Taylor A Jr, Clark S, Ball T. Comparison of Tc-99m MAG3 and Tc-99m DTPA scintigraphy in neonates. Clin Nucl Med 1994; 19:575.</a></li><li><a class="nounderline abstract_t">Gordon I. Diuretic renography in infants with prenatal unilateral hydronephrosis: an explanation for the controversy about poor drainage. BJU Int 2001; 87:551.</a></li><li><a class="nounderline abstract_t">Koff SA. Postnatal management of antenatal hydronephrosis using an observational approach. Urology 2000; 55:609.</a></li><li><a class="nounderline abstract_t">Gordon I, Dhillon HK, Gatanash H, Peters AM. Antenatal diagnosis of pelvic hydronephrosis: assessment of renal function and drainage as a guide to management. J Nucl Med 1991; 32:1649.</a></li><li><a class="nounderline abstract_t">de Bruyn R, Marks SD. Postnatal investigation of fetal renal disease. Semin Fetal Neonatal Med 2008; 13:133.</a></li><li><a class="nounderline abstract_t">Grattan-Smith JD, Little SB, Jones RA. MR urography evaluation of obstructive uropathy. Pediatr Radiol 2008; 38 Suppl 1:S49.</a></li></ol></div><div id="topicVersionRevision">Topic 6105 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10792187" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Antenatally detected pelvi-ureteric junction obstruction: concerns about conservative management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2197441" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The postnatal management of hydronephrosis diagnosed by prenatal ultrasound.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8351759" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Post-natal management of antenatally detected, bilateral hydronephrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23416643" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diagnostic accuracy of renal pelvic dilatation for detecting surgically managed ureteropelvic junction obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16813930" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The magnitude of fetal renal pelvic dilatation can identify obstructive postnatal hydronephrosis, and direct postnatal evaluation and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32984198" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Grading of Hydronephrosis: An Ongoing Challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25435247" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Multidisciplinary consensus on the classification of prenatal and postnatal urinary tract dilation (UTD classification system).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30636381" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Value of renal pelvic diameter and urinary tract dilation classification in the prediction of urinary tract anomaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34453601" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Postnatal urinary tract dilatation classification: improvement of the accuracy in predicting kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34100626" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Evaluation of Urinary Tract Dilation Classification System for Prediction of Long-Term Outcomes in Isolated Antenatal Hydronephrosis: A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31914077" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Validation of "urinary tract dilation" classification system: Correlation between fetal hydronephrosis and postnatal urological abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27916387" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Six of one, half a dozen of the other: A measure of multidisciplinary inter/intra-rater reliability of the society for fetal urology and urinary tract dilation grading systems for hydronephrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19002723" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antenatal renal pelvis dilatation: 2-year follow-up with DMSA scintigraphy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32577807" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Antenatally detected urinary tract dilatation: a 12-15-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17129977" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Is screening for vesicoureteral reflux mandatory in infants with antenatal renal pelvis dilatation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11849184" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Postnatal management of antenatal hydronephrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34386854" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Contrast-enhanced voiding urosonography part 2: urethral imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22850807" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Children and adolescents with ureteropelvic junction obstruction: is an additional voiding cystourethrogram necessary? Results of a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27888411" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : To screen or not to screen for vesicoureteral reflux in children with ureteropelvic junction obstruction: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19582482" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Outcome and management of isolated moderate renal pelvis dilatation detected at postnatal screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22350369" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Natural history of bilateral mild isolated antenatal hydronephrosis conservatively managed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16362721" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Outcome of isolated antenatal hydronephrosis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18499166" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Late recurrence of symptomatic hydronephrosis in patients with prenatally detected hydronephrosis and spontaneous improvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1437359" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Urinary tract infection in infants in spite of prenatal diagnosis of hydronephrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17482945" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Antenatal hydronephrosis and the risk of pyelonephritis hospitalization during the first year of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27919407" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Incidence of urinary tract infections in infants with antenatally diagnosed hydronephrosis-A retrospective single center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29880703" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Neonatal Circumcision and Urinary Tract Infections in Infants With Hydronephrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31462436" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Frequency of urinary tract infection in children with antenatal diagnosis of urinary tract dilatation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18001783" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Risk factors for urinary tract infection in children with prenatal renal pelvic dilatation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22704090" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Do infants with mild prenatal hydronephrosis benefit from screening for vesicoureteral reflux?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23248229" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Antibiotic prophylaxis for urinary tract infections in antenatal hydronephrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18560902" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Antenatal hydronephrosis: infants with minor postnatal dilatation do not need prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8326642" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Diuretic renography in the evaluation of neonatal hydronephrosis: is it reliable?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7924094" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Comparison of Tc-99m MAG3 and Tc-99m DTPA scintigraphy in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11298056" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Diuretic renography in infants with prenatal unilateral hydronephrosis: an explanation for the controversy about poor drainage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10792062" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Postnatal management of antenatal hydronephrosis using an observational approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1880563" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Antenatal diagnosis of pelvic hydronephrosis: assessment of renal function and drainage as a guide to management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18249044" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Postnatal investigation of fetal renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18071689" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : MR urography evaluation of obstructive uropathy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
